Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 20/20 | 0.82 |
| ▸ | GNA15 | P30679 | 1/20 | 0.69 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.69 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.69 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.69 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17911211 | 1.00 | FFAR1 (0.82) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16515535 | 0.92 | FFAR1 (0.82) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16532904 | 0.92 | FFAR1 (0.82) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL17911281 | 0.92 | FFAR1 (0.82) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL17911232 | 0.91 | FFAR1 (0.74) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16515286 | 0.91 | FFAR1 (0.74) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL206009 | 0.90 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16532834 | 0.89 | FFAR1 (0.68) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16515288 | 0.89 | FFAR1 (0.68) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL17911225 | 0.89 | FFAR1 (0.68) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | KANG, XINSHAN (CN) | 2016-07-14 | — | — | US | claimed |
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | KANG, XINSHAN (CN) | 2016-07-14 | — | — | US | disclosed |
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | KANG, XINSHAN (CN) | 2016-07-14 | — | — | US | disclosed |
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | KANG, XINSHAN (CN) | 2016-07-14 | — | — | US | disclosed |
| WO-2015024526-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2015-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | GPR119, GLP1R, INSR | FFAR1 9/4885GNA15 1628/4885SLC10A1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.